 SHANGHAI and GAITHERSBURG, Md., July 9, 2021 PRNewswire -- I-Mab the Company Nasdaq: IMAB, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the signing of two new collaborations with emerging biotech companies in China to strengthen its next-generation innovation pipeline. 